

can be utilized to detect toxic mechanisms that are unrelated to pharmacokinetics, such as formation of reactive metabolite that are normally not detected in biofluids. The identification of the issues early during drug discovery and drug evaluation can help make informed go/no go decisions as well as ensure design of a well-defined clinical program. As a result, drug evaluation programs can be terminated at an early stage before futile investments are made or can be launched into clinical development with a high degree of success.

REFERENCES

1. Prentice RA, Lis Y, Walker SR. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964–1985). *Br J Clin Pharmacol* 1988; 25:387–396.
2. Kennedy T. Managing the drug discovery/development interface. *Drug Discov Today* 1997; 2:436–444.
3. Venkatesh S, Lipper RA. Role of the development scientist in compound lead selection and optimization. *J Pharm Sci* 2000; 89:145–154.
4. Krishnan K, Andersen ME. Interspecies scaling in pharmacokinetics. In: Rescigno A, Thakur AK, eds. *New Trends in Pharmacokinetics*. New York and London: Plenum Press, 1991:203–225.
5. Mahmood I. Prediction of clearance in humans from in vitro human liver microsomes and allometric scaling. A comparative study of the two approaches. *Drug Metab Drug Interact* 2002; 19:49–64.
6. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. *J Pharmacol Toxicol Methods* 2000; 44:235–249.
7. Wenlock MC, Austin RP, Barton P, Davis AM, Lesson PD. A comparison of physicochemical property profiles of development and marketed drugs. *J Med Chem* 2003; 46:1250–1256.
8. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv Drug Deliv Rev* 1997; 23:3–25.
9. Kramer SD, Wunderli-Allenspach H. Physicochemical properties in pharmacokinetic lead optimization. *IL Farmaco* 2001; 56:145–148.
10. Kerns EH. High throughput physicochemical profiling for drug discovery. *J Pharmaceut Sci* 2001; 90:1838–1858.
11. Rhodes CT. In: Welling PG, Tse FLS, eds. *Drug Delivery Systems: Effects of Pharmacokinetics on Design, Evaluation and Production*. New York: Marcel Dekker, 1995:39–58.
12. Tse FLS, Jaffe JM. *Preclinical Drug Disposition: A Laboratory Handbook*. Drugs and the Pharmaceutical Sciences. New York: Marcel Dekker, 1991:46:118–142.
13. Fleisher D, Li C, Zhou Y, Pao LH, Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration: clinical implications. *Clin Pharmacokinet* 1999; 36:233–254.